Obesity
Test your knowledge of pediatric obesity classification, causes, and clinical guidelines with this interactive quiz.
Dr. Cho Han Chiang reviews GI risks of GLP-1 RAs, balancing safety with their metabolic and cardiovascular benefits.
Once-daily oral therapy shows strong efficacy in obesity, with regulatory submission expected by the end of 2025.
Dr. Angelo Avogaro explains how incretin hormones support cardiovascular and metabolic health in type 2 diabetes treatment.
Dr. Neil Iyengar discusses how metabolic dysfunction impacts cancer risk, progression, and response to treatment.
Emerging therapies targeting metabolism may improve cancer care and survivorship, Dr. Neil Iyengar explains.
How much do you know about obesity? Test your clinical IQ with this quick quiz for healthcare professionals.
Tirzepatide improved testosterone, body composition, sexual function in men with obesity-related hypogonadism, study finds.
Semaglutide improves liver health in MASH via weight loss and proteomic pathways, per a new Nature Medicine study.
Once-weekly semaglutide improved weight, insulin needs, and glycemic control in adults with T1D and obesity.
Amycretin shows significant weight loss and tolerability in early trial, supporting further study for obesity treatment.
ADA’s new clinical guidelines aim to eliminate weight stigma and bias in obesity care across US healthcare settings.
Evidence-based tips on GLP-1s, nutrition, exercise, and mindset to support sustainable weight loss and better health.
Personalized obesity care combining medication and lifestyle delivers better, longer-lasting weight loss and health outcomes.
When diet and exercise wave the white flag, real medicine rolls in like the superhero with a prescription pad!
Dr. Alex McDonald and Dr. Regina Ragasa explore obesity’s health impact and a multifaceted approach for effective care.
Orforglipron, a daily oral GLP-1 pill, matches Ozempic in Phase 3 trial, offering a needle-free option for Type 2 diabetes.
Black youth with dysglycemia show reduced insulin clearance, possibly contributing to β-cell dysfunction and ...
Real-world weight loss with semaglutide or tirzepatide is lower due to early discontinuation and low maintenance dosing.
Nearly half of U.S. patients discontinued semaglutide within 5 months, with cost a key barrier to continued use.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.